Hospira Reports Third-Quarter 20...(rations particularly in comparing und...),Health

Date:10/27/2009

rations, particularly in comparing underlying results from period to period. Management uses these Non-GAAP financial measures internally in financial planning, to monitor business unit performance, and in evaluating management performance. All Non-GAAP financial measures are intended to supplement the applicable GAAP measures and should not be considered in isolation from, or a replacement for, financial measures prepared in accordance with GAAP. Hospira's Non-GAAP financial measures may be different from Non-GAAP financial measures used by other companies. Three months ended September 30, 2009 Reconciliation of GAAP to Non-GAAP Financial Measures: ------------------------------------------------------------------------ Income Gross From Net Diluted Profit (1) Operations Income EPS --------- ---------- ------ ------- GAAP financial measures $395.6 $161.5 $116.2 $0.71 Specified items: Project Fuel charges (A) 7.8 27.4 20.9 0.13 Facilities Optimization charges (B) 1.5 4.8 3.1 0.02 Amortization of Mayne Pharma intangible assets (C) 13.5 13.5 7.2 0.04 --------- ---------- ------ ------- Adjusted financial measures $418.4 $207.2 $147.4 $0.90 ========= ========== ====== ======= GAAP results for the three months ended September 30, 2009 include: A -- Project Fuel charges: $7.8 million reported in Cost of products sold, $10.5 million reported in Restructuring and impairment, $1.3 million reported in Research and development and $7.
'/>"/>

SOURCE Hospira, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs